Joshua Meeks

15PUBLICATIONS
115CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersInnate immunityNeurology and neuromuscular diseasesMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Oct 15, 2026
Combination therapy for BCG-unresponsive non-muscle-invasive bladder cancer: biological rationale and ongoing clinical strategies.

|Oct 01, 2026
Evaluation of Urinary Circulating Tumor DNA to Detect Minimal Residual Disease in Patients with High-Risk Non-Muscle Invasive Bladder Cancer.

|Sep 09, 2026
Integrating NECTIN4 Amplification With Membranous Nectin-4 Expression to Develop a Scoring System for Predicting Enfortumab Vedotin Response in Urothelial Carcinoma.

|Jan 02, 2026
STING/type I interferon pathway is required for antigen-containing PLGA nanoparticle- and apoptotic cell-induced CD4+ T cell tolerance.

Joseph R Podojil, Andrew C Cogswell, Tobias Neef

|Sep 10, 2025
Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies.

Lexiaochuan Wen, Hiroko Miyagi, Philippe E Spiess

|Dec 03, 2024
Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review.

Emanuele Crupi, Tiago Costa de Padua, Laura Marandino

Pageof 3

Frequent Collaborators

5 joint publications

Ashish M Kamat

4 joint publications

Roger Li

2 joint publications

Oliver Hahn

2 joint publications

Joseph R Podojil